Ligand agrees to fund AvenCell's CAR-T pipeline for up to $47 million
The royalty aggregator will back AvenCell's switchable CAR-T programs AVC-201 and AVC-203 through a tranched financing tied to clinical milestones.
SEC filing
Latest
4 stories
Thursday, September 24
Tuesday, September 22
Ligand pays $23 million for royalty rights on Santen's myopia drug Ryjunea
Ligand acquired the royalty and milestone interest in Ryjunea from Sydnexis, gaining tiered royalties on Santen's sales across Europe, the Middle East, and Africa.
SEC filing
Thursday, August 6
Ligand raises EPS guidance floor, closes XOMA Royalty deal, reports pipeline progress
Filspari's FSGS launch, Capvaxive's pediatric expansion, and volixibat's Breakthrough Therapy tag headline a quarter that also saw a $700 million convertible note deal and the XOMA acquisition close.
SEC filing
Tuesday, July 14
Ligand closes $739 million acquisition of XOMA Royalty
The deal adds seven marketed royalty products and more than 100 development-stage assets to Ligand's portfolio.
SEC filing